Friday, Novavax Inc (NASDAQ: NVAX) entered a co-exclusive licensing agreement with Sanofi SA (NASDAQ:SNY) for COVID-19 and flu-COVID-19 combination vaccines. The terms of the agreement include: A co-exclusive license to co-commercialize Novavax’s current stand-alone adjuvanted COVID-19 vaccine worldwide (except in countries with existing Advance Purchase Agreements and India, Japan, and South Korea where Novavax has existing partnership agreements). Novavax has a sole license to its adjuvanted COVID-19 vaccine for use in combination with Sanofi’s flu vaccines, while Novavax retains the right to and is developing its own COVID-19-Influenza Combination vaccine candidate. A non-exclusive license to use Novavax’s adjuvanted COVID-19 vaccine in combination with non-flu vaccines. A non-exclusive license to use the Matrix-M adjuvant in vaccine products. Novavax will receive an ...